DE69612375D1 - Substrate für beta-lactamase und deren verwendung - Google Patents

Substrate für beta-lactamase und deren verwendung

Info

Publication number
DE69612375D1
DE69612375D1 DE69612375T DE69612375T DE69612375D1 DE 69612375 D1 DE69612375 D1 DE 69612375D1 DE 69612375 T DE69612375 T DE 69612375T DE 69612375 T DE69612375 T DE 69612375T DE 69612375 D1 DE69612375 D1 DE 69612375D1
Authority
DE
Germany
Prior art keywords
beta
group
lactamase
substrates
chr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69612375T
Other languages
English (en)
Other versions
DE69612375T2 (de
Inventor
Y Tsien
Gregor Zlokarnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69612375D1 publication Critical patent/DE69612375D1/de
Publication of DE69612375T2 publication Critical patent/DE69612375T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36—Methylene radicals, substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C12P17/184—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system containing a beta-lactam ring, e.g. thienamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2415/00—Assays, e.g. immunoassays or enzyme assays, involving penicillins or cephalosporins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/805—Test papers
DE69612375T 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung Expired - Lifetime DE69612375T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/407,544 US5741657A (en) 1995-03-20 1995-03-20 Fluorogenic substrates for β-lactamase and methods of use
PCT/US1996/004059 WO1996030540A2 (en) 1995-03-20 1996-03-20 Substrates for beta-lactamase and uses thereof

Publications (2)

Publication Number Publication Date
DE69612375D1 true DE69612375D1 (de) 2001-05-10
DE69612375T2 DE69612375T2 (de) 2001-10-31

Family

ID=23612529

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69612375T Expired - Lifetime DE69612375T2 (de) 1995-03-20 1996-03-20 Substrate für beta-lactamase und deren verwendung
DE69630622T Expired - Lifetime DE69630622T2 (de) 1995-03-20 1996-03-20 Nukleinsäuren und deren Verwendung zur Bestimmung von Beta-Laktamase

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69630622T Expired - Lifetime DE69630622T2 (de) 1995-03-20 1996-03-20 Nukleinsäuren und deren Verwendung zur Bestimmung von Beta-Laktamase

Country Status (13)

Country Link
US (5) US5741657A (de)
EP (3) EP0817785B1 (de)
JP (2) JP3633940B2 (de)
CN (2) CN1066731C (de)
AT (3) ATE253632T1 (de)
AU (1) AU723164B2 (de)
CA (1) CA2215310C (de)
DE (2) DE69612375T2 (de)
DK (2) DK0982398T3 (de)
ES (2) ES2209305T3 (de)
MX (1) MX9707213A (de)
PT (1) PT982398E (de)
WO (1) WO1996030540A2 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821727B1 (en) 1993-11-15 2004-11-23 Applera Corporation Hybridization assay using self-quenching fluorescence probe
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US20070020715A1 (en) * 1995-03-20 2007-01-25 The Regents Of The University Of California Novel fluorogenic substrates for beta-lactamase gene expression
US7427680B2 (en) * 2001-01-12 2008-09-23 The Regents Of The University Of California Fluorogenic substrates for BETA-lactamase gene expression
US20040157262A1 (en) * 1996-04-30 2004-08-12 Michel Kohl Conjugates of haptens to beta-lactam derivatives and their use for detecting and/or quantifying haptens in solution and device for implementation thereof
US5945526A (en) * 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5800996A (en) * 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US7388092B2 (en) * 1996-05-03 2008-06-17 Applera Corporation Oligonucleotides and analogs labeled with energy transfer dyes
US7825237B2 (en) * 1996-05-03 2010-11-02 Applied Biosystems, Llc Oligonucleotides and analogs labeled with energy transfer dyes
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US6593135B2 (en) * 1996-08-16 2003-07-15 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Long wavelength engineered fluorescent proteins
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
FI963989A (fi) * 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
CN1254383A (zh) * 1997-05-01 2000-05-24 美国3M公司 基于染料二聚作用的生荧光蛋白水解酶底物
US6200762B1 (en) * 1997-08-01 2001-03-13 Aurora Biosciences Corporation Photon reducing agents and compositions for fluorescence assays
US6214563B1 (en) * 1997-08-01 2001-04-10 Aurora Biosciences Corporation Photon reducing agents for reducing undesired light emission in assays
US6221612B1 (en) * 1997-08-01 2001-04-24 Aurora Biosciences Corporation Photon reducing agents for use in fluorescence assays
US6689574B1 (en) 1997-10-07 2004-02-10 Merck & Co., Inc. Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
JP2002502859A (ja) * 1998-02-05 2002-01-29 メルク エンド カムパニー インコーポレーテッド 新規ｇａｂａｂ受容体ｄｎａ配列
US6284461B1 (en) 1998-04-28 2001-09-04 Aurora Biosciences Corporation Use of inhibitors in reporter assays
US6031094A (en) * 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US6051395A (en) * 1998-08-25 2000-04-18 Biometric Imaging, Inc. Method and compound for detecting low levels of microorganisms
US6420130B1 (en) 1998-12-14 2002-07-16 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
US6514687B1 (en) 1998-12-14 2003-02-04 Vertex Pharmaceuticals (San Diego), Llc Optical molecular sensors for cytochrome P450 activity
US6143492A (en) * 1998-12-14 2000-11-07 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
AU3119000A (en) * 1998-12-14 2000-07-03 Invitrogen Corporation Optical molecular sensors for cytochrome p450 activity
US8148110B2 (en) * 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
WO2000071702A1 (en) * 1999-05-25 2000-11-30 Panorama Research, Inc. Interaction-activated proteins
US6218124B1 (en) 1999-08-27 2001-04-17 Pe Corporation Method for detecting oligonucleotides using UV light source
US6358684B1 (en) 1999-08-27 2002-03-19 Pe Corporation UV excitable fluorescent energy transfer dyes
EP1230380B1 (de) 1999-11-05 2004-02-11 Iconix Pharmaceuticals, Inc. Enzym-substrate und assay mit intramolekularen fret
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US6692965B1 (en) * 1999-11-23 2004-02-17 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
AU2001236475A1 (en) * 2000-01-13 2001-07-24 Panorama Research, Inc. Circularly permutated, interaction-activated proteins
CA2398010A1 (en) 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
EP1254369B1 (de) 2000-02-08 2010-10-06 Sangamo BioSciences, Inc. Zellen zur entdeckung von medikamenten
EP1259599A4 (de) * 2000-02-17 2003-08-20 Merck & Co Inc Zellfusionstests mittels fluoreszenzresonanzenergietransfer
US20040171107A1 (en) * 2000-02-23 2004-09-02 David Nelson Modified flourescent proteins
EP1143013A1 (de) 2000-04-03 2001-10-10 Warner-Lambert Company Verfahren und Zusammenzetzungen zur Screening von ICRAC-Modulatoren
EP1143017A3 (de) * 2000-04-03 2004-01-28 Warner-Lambert Company LLC Methoden und Zusammensetzungen zum Screenen von icrac Modulatoren
US6806289B1 (en) 2000-07-14 2004-10-19 Stephen J. Lippard Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1385853A4 (de) * 2001-01-12 2005-02-16 Univ California Beta-lactamase-substrate mit phenolischen ethern
US6850317B2 (en) * 2001-01-23 2005-02-01 Schlumberger Technology Corporation Apparatus and methods for determining velocity of oil in a flow stream
US7142306B2 (en) * 2001-01-23 2006-11-28 Schlumberger Technology Corporation Optical probes and probe systems for monitoring fluid flow in a well
US7005511B2 (en) 2001-02-26 2006-02-28 The Regents Of The University Of California Fluorescent protein variants and methods for making same
EP1368058A4 (de) * 2001-03-02 2005-01-12 Merck & Co Inc Virale reporter-partikel
AU2002354569A1 (en) * 2001-07-12 2003-01-29 Merck And Co., Inc. Electrical field stimulation of eukaryotic cells
US20030104604A1 (en) * 2001-08-03 2003-06-05 Weiping Yang Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
AU2002367060A1 (en) * 2001-12-21 2003-07-30 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20050181464A1 (en) * 2002-04-04 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
ES2197811B2 (es) * 2002-04-05 2005-05-01 Universidad Complutense De Madrid Sintesis de derivados fluorescentes de antiobioticos beta-lactamicos.
EP1499748B1 (de) * 2002-04-16 2009-03-25 Merck & Co., Inc. Hepatitis-c-virus-testsysteme
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
US20040115742A1 (en) * 2002-06-28 2004-06-17 Ruoying Tan Method to identify specific interaction between ligand and receptor
EP1543128A4 (de) * 2002-07-18 2008-02-20 Invitrogen Corp Virusvektoren mit rekombinationsstellen
WO2004040008A1 (ja) * 2002-10-29 2004-05-13 Showa Yakuhin Kako Co.,Ltd. β−ラクタマーゼ検出試薬組成物、検出キット及び検出方法
DE60330985D1 (de) 2002-11-01 2010-03-04 Univ New York State Res Found Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
EP1613160A4 (de) 2003-03-27 2008-01-02 Ptc Therapeutics Inc Betrachtung von enzymen des trna-splice-wegs zur identifikation von antifungalen und/oder proliferationshemmenden molekülen
CA2520415A1 (en) 2003-03-27 2004-10-14 Ptc Therapeutics, Inc. Methods of identifying compounds that target trna splicing endonuclease and uses of said compounds as anti-proliferative agents
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
US7473548B2 (en) 2003-04-25 2009-01-06 Medtronic, Inc. Optical detector for enzyme activation
JP4391523B2 (ja) 2003-04-30 2009-12-24 オーロラ ディスカバリー インコーポレイティッド 高密度保存およびアッセイプラットフォームを提供するマルチウェルプレート
US7399639B2 (en) * 2003-05-04 2008-07-15 Massachusetts Institute Of Technology Sensors, and methods of making and using the same
GB0311948D0 (en) * 2003-05-23 2003-06-25 Stockport Innovation Ltd Light emitting probes
EP1644538A4 (de) * 2003-06-26 2006-11-08 Invitrogen Corp Verfahren und zusammensetzungen zum nachweis von promotoraktivität und zur expression von fusionsproteinen
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
EP2484687A3 (de) 2003-08-08 2012-11-14 Life Technologies Corporation Verfahren und Zusammensetzungen zum nahtlosen Klonieren von Nukleinsäuremolekülen
US7304168B2 (en) * 2003-08-14 2007-12-04 Board Of Regents, University Of Texas System Photo-caged fluorescent molecules
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20080057529A1 (en) * 2003-12-18 2008-03-06 Michele Pallaoro Method for Identifying Histone Deacetylase Inhibitors
WO2005071096A2 (en) 2004-01-21 2005-08-04 Molecular Probes, Inc. Derivatives of cephalosporin and clavulanic acid for detecting beta-lacamase in a sample
MXPA06009423A (es) * 2004-02-18 2007-04-02 Chromocell Corp Metodos y materiales que utilizan soluciones de ensayo para senalizacion.
KR100663038B1 (ko) 2004-07-22 2007-01-02 학교법인 명지학원 외부유전자의 발현 및 단백질의 분비를 위한 벡터 ｐＭＳＧ1220
KR20080028964A (ko) 2005-06-27 2008-04-02 엑셀리시스, 인코포레이티드 피라졸계 ｌｘｒ 변조제
FR2889700B1 (fr) * 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
DE102005044071A1 (de) * 2005-09-07 2007-03-08 Nimbus Biotechnologie Gmbh Verfahren zur Messung der Permeation einer Substanz durch eine Barriere
US8092784B2 (en) * 2005-11-30 2012-01-10 Biotium, Inc. Enzyme substrate comprising a functional dye and associated technology and methods
CN100487435C (zh) * 2005-12-22 2009-05-13 云南农业大学 一种松树萎蔫病病原线虫的检测方法
US20070218456A1 (en) * 2006-02-08 2007-09-20 Invitrogen Corporation Cellular assays for signaling receptors
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
US20110065595A1 (en) * 2007-04-12 2011-03-17 Nathan Citri Method and Test Kit for the Rapid Identification and Characterization of Cells
US8097434B2 (en) 2007-10-19 2012-01-17 Becton, Dickinson And Company Methods for the detection of beta-lactamases
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US7867758B2 (en) * 2008-04-01 2011-01-11 The Board Of Trustees Of The Leland Stanford Junior University Bioluminogenic assay system for measuring beta-lactamase activity
EP3056497B1 (de) 2008-05-05 2018-08-29 The General Hospital Corporation Verfahren unter verwendung von bodipy-markierten enzymsubstraten
BRPI0917478A8 (pt) * 2008-08-06 2017-05-23 Univ Leland Stanford Junior uso de beta-lactamase bacteriana para diagnóstico in vitroe geração de imagem, diagnóstico e terapêutica in vivo
US9834807B2 (en) 2008-10-20 2017-12-05 Becton, Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular micororganism targets
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
WO2010068747A1 (en) 2008-12-12 2010-06-17 University Of Florida Research Foundation, Inc. Cell-based detection of apf through its interaction with ckap4 for diagnosis of interstitial cystitis
US8431416B2 (en) 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
AU2010230985B2 (en) 2009-04-03 2015-09-24 United Kingdom Research And Innovation Mutants of activation-induced cytidine deaminase (AID) and methods of use
WO2010129779A1 (en) * 2009-05-07 2010-11-11 Biomerieux, Inc. Methods for antimicrobial resistance determination
US9400273B1 (en) 2009-12-09 2016-07-26 Life Technologies Corporation 7-hydroxycoumarin-based cell-tracking reagents
US8318953B2 (en) * 2010-06-23 2012-11-27 Aat Bioquest, Inc. Reactive coumarin derivatives and their use in cellular analyses
CN102115780B (zh) * 2010-12-15 2013-01-30 黑龙江省乳品工业技术开发中心 一种检测β-内酰胺酶的试剂盒及其制备和检测方法
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013053953A1 (en) * 2011-10-14 2013-04-18 Université de Liège Method for measuring beta-lactam antibiotics
CN103509083B (zh) * 2012-06-28 2016-06-08 王郁生 一种广谱β-内酰胺酶荧光底物及其制备方法和应用
KR102055438B1 (ko) 2012-07-31 2019-12-19 에이지엑스 쎄라퓨틱스, 인크. Hla g-변형된 세포 및 방법
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP3151866B1 (de) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimäre kapside
WO2016028804A1 (en) 2014-08-21 2016-02-25 Discoverx Corporation Homogenous thermal shift ligand binding assay
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016115503A1 (en) 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
CN104714006B (zh) * 2015-02-04 2017-10-20 国家纳米科学中心 一种检测奶制品中β‑内酰胺酶的方法
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
EP3448987A4 (de) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
EP3458589A4 (de) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus huntington
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
EP3506817A4 (de) 2016-08-30 2020-07-22 The Regents of The University of California Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
CN108623617B (zh) * 2017-03-22 2021-04-02 蒋辉 一种头孢噻呋中间体的制备方法
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
US10739331B2 (en) * 2017-08-11 2020-08-11 Bioventures, Llc OMA1 activity assay
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP3697908A1 (de) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
US20210236644A1 (en) 2017-11-10 2021-08-05 Cocoon Biotech Inc. Ocular applications of silk-based products
EP3762500A1 (de) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
CN112313331A (zh) 2018-04-27 2021-02-02 沃雅戈治疗公司 用于测量aadc病毒载体效力的方法
EP3793616A1 (de) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur aav-freisetzung
US20210198691A1 (en) 2018-05-15 2021-07-01 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
JP2022500066A (ja) 2018-09-28 2022-01-04 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
EP3966227A1 (de) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
EP4135841A1 (de) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau-bindende verbindungen
WO2021230987A1 (en) 2020-05-13 2021-11-18 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
CN111621492B (zh) * 2020-06-15 2021-10-26 安徽红杉生物医药科技有限公司 内酰胺酶及其应用和酶法拆分制备(1r，4s)-文斯内酯的方法
MX2023000815A (es) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos neurologicos relacionados con la deficiencia de glucosilceramidasa beta.
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
AU2021421391A1 (en) 2021-01-24 2023-07-20 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023091949A2 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563876B2 (de) * 1973-06-22 1981-01-27
JPS534810B2 (de) 1975-02-13 1978-02-21
US4234683A (en) * 1978-11-24 1980-11-18 Mcmillan William A Beta-lactamase diagnostic product and method
DE2916433A1 (de) * 1979-04-24 1980-11-13 Hoechst Ag Chromophore cephalosporine und verfahren zu ihrer herstellung
DE3019451A1 (de) * 1980-05-21 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und reagens zur bestimmung von (beta) -lactamasen
FR2494279A1 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouvelles oxacephalosporines, leur preparation et les medicaments qui les contiennent
US4740459A (en) * 1984-08-06 1988-04-26 Washington Research Foundation Fluorescence assay for microbial beta-lactamase
US4760018A (en) * 1985-06-17 1988-07-26 Penicillin Assays, Inc. Rapid method for the detection of beta-lactamase in body fluids
US4764462A (en) * 1985-08-23 1988-08-16 Georgetown University Detectably labeled cephalosporin assay for beta-lactamase
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
GB8819104D0 (en) * 1988-08-11 1988-09-14 Beecham Group Plc Novel compounds
US4978613A (en) * 1989-01-17 1990-12-18 Abbott Laboratories Beta-lactamase assay employing chromogenic precipitating substrates
CA2045129A1 (en) * 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
CA2076975A1 (en) * 1990-02-28 1991-08-29 Kevin W. Moore Mammalian expression vectors
US5264346A (en) * 1991-06-03 1993-11-23 Chen Kirk C S Colorimetric method for beta-lactamase assay and its applications
US5162524B1 (en) * 1991-06-06 1997-06-17 Bristol Myers Squibb Co Processes for making cephems from allenylazetidinone derivatives
US5639596A (en) * 1991-08-16 1997-06-17 Gsf-Forschungszentrum Fur Umweltund Gesundheit DNA construct and in vitro test for detecting tumor promoters by means of said DNA construct
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
US5338843A (en) * 1992-01-30 1994-08-16 Becton, Dickinson And Company Fluorogenic and chromogenic β-lactamase substrates
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
GB9523703D0 (en) * 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US5955604A (en) * 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof

Also Published As

Publication number Publication date
CA2215310A1 (en) 1996-10-03
EP1405922A2 (de) 2004-04-07
ATE521715T1 (de) 2011-09-15
EP1405922B1 (de) 2011-08-24
US6291162B1 (en) 2001-09-18
EP0982398A1 (de) 2000-03-01
EP1405922A3 (de) 2004-09-29
EP0817785B1 (de) 2001-04-04
US20030119085A1 (en) 2003-06-26
DE69630622D1 (de) 2003-12-11
DE69630622T2 (de) 2004-09-23
JPH11502714A (ja) 1999-03-09
WO1996030540A2 (en) 1996-10-03
DE69612375T2 (de) 2001-10-31
MX9707213A (es) 1998-07-31
EP0817785A2 (de) 1998-01-14
DK0982398T3 (da) 2004-02-16
US20070184513A1 (en) 2007-08-09
ES2156994T3 (es) 2001-08-01
JP3633940B2 (ja) 2005-03-30
AU5526696A (en) 1996-10-16
CN1184479A (zh) 1998-06-10
US6472205B1 (en) 2002-10-29
JP3856807B2 (ja) 2006-12-13
CA2215310C (en) 2002-05-21
JP2005021172A (ja) 2005-01-27
EP0982398B1 (de) 2003-11-05
DK0817785T3 (da) 2001-07-02
PT982398E (pt) 2004-02-27
US7157575B2 (en) 2007-01-02
US8071761B2 (en) 2011-12-06
CN1296078A (zh) 2001-05-23
AU723164B2 (en) 2000-08-17
ATE253632T1 (de) 2003-11-15
ES2209305T3 (es) 2004-06-16
CN1066731C (zh) 2001-06-06
CN1213144C (zh) 2005-08-03
US5741657A (en) 1998-04-21
WO1996030540A3 (en) 1997-01-09
ATE200287T1 (de) 2001-04-15

Similar Documents

Publication Publication Date Title
DE69612375T2 (de) Substrate für beta-lactamase und deren verwendung
EP0767382A3 (de) Fluoreszierende Verbindungen und deren Verwendung zum Messen von Reticulozyten
DE69115812T2 (de) Latente Carbamat-Silizium-Haftvermittler und Verfahren zu deren Herstellung und Verwendung
HU9502811D0 (en) N-acyl-sulfamic acid esters (or thioesters), n-acyl-sulfonamides and n-sulfonyl-carbamic-acid-esters (or thioesters) as hypercholesterolemic agents
CA2009925A1 (en) Method for enhancement of chemiluminescence
WO2006085978A3 (en) Conjugates of a cephalosporin derivative and a fluorophor precursor and related compounds as substrates for beta-lactamase gene expression
DE3580638D1 (de) Pyrrolderivate, verfahren zu ihrer herstellung und ihre verwendung als pestizide.
ATE285238T1 (de) Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl- phenol derivaten
AT397654B (de) Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
ES8605249A1 (es) Un procedimiento para la preparacion de tiazolidinas
ATE184003T1 (de) 4-iminochinoline, verfahren zu ihrer herstellung und ihre verwendung
EP0416514A3 (en) Method for specific determination of pancreatic alpha-amylase
ATE171936T1 (de) Salpetersäureester von 2-(2,6-dihalophenylamino) phenylacetoessigsäurederivaten und verfahren zu ihrer herstellung
ES8303434A1 (es) Procedimiento para la obtencion de amidas del ester de acido fosforico (fosfonico).
WO2002068678A3 (en) Beta-lactamase substrates having phenolic ethers
AU5640286A (en) Intermediates for organophosphate insecticides
PT98699A (pt) Processo de acidos acilaminometanofosfonicos e de acidos acilaminometil-fosfinicos
BR9100971A (pt) Compostos,processo para preparacao dos compostos e compostos arila-propila-aminicos
ATE80882T1 (de) (ethylenedioxo-3,3 zyclohexyl)-4 aketophenon und derivate davon, verfahren zu deren herstellung und verwendung dieser verbindungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition